UTRECHT, The Netherlands and STAMFORD, Conn. , Dec. 17, 2020 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multi-specific antibodies (Biclonics® and Triclonics TM ), and Sem a 4 , a patient-centered health intelligence company,

UTRECHT, The Netherlands and CAMBRIDGE, Mass. , Nov. 16, 2020 (GLOBE NEWSWIRE) -- Merus N.V.  (Nasdaq:MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ®  and Triclonics™), today announced that Bill Lundberg, M.D., President and Chief

UTRECHT, The Netherlands and CAMBRIDGE, Mass. , Nov. 09, 2020 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics™), today announced that

– Clinical data and program update planned for lead program Zenocutuzumab (“Zeno”) in 2Q 2021 – – MCLA-129 expected to enter clinic in 2021 – UTRECHT, The Netherlands and CAMBRIDGE, Mass. , Nov. 05, 2020 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a

UTRECHT, The Netherlands , and CAMBRIDGE, Mass. , Oct. 12, 2020 (GLOBE NEWSWIRE) -- myTomorrows, a global health technology company, and Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics™), today

UTRECHT , The Netherlands, and CAMBRIDGE, Mass. , Aug. 07, 2020 (GLOBE NEWSWIRE) -- Merus N.V.  (Nasdaq:MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics™), today announced that Bill Lundberg , M.D., President and Chief

– Lead program Zenocutuzumab remains on track – – Dr. Andrew Joe appointed Chief Medical Officer – – Merus extends cash runway into 2H 2022 – UTRECHT, The Netherlands and CAMBRIDGE, Mass. , Aug. 06, 2020 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a

UTRECHT, The Netherlands and CAMBRIDGE, Mass. , July 27, 2020 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics™) for cancer, today announced that the U.S.

Dr. Joe brings seasoned research and development leadership and deep expertise in the clinical development of immuno-oncology, antibody, and targeted therapies for cancer UTRECHT, The Netherlands and CAMBRIDGE, Mass. , July 27, 2020 (GLOBE NEWSWIRE) -- Merus N.V.

Caris to provide DNA and RNA molecular testing to support  patient identification and enrollment for Merus’ Zenocutuzumab Phase 1/2 eNRGy trial UTRECHT, The Netherlands and CAMBRIDGE, Mass. and IRVING, Texas , July 13, 2020 (GLOBE NEWSWIRE) -- Merus N.V.

UTRECHT, The Netherlands and CAMBRIDGE, Mass. , June 01, 2020 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics™), today announced that

– MCLA-128, zenocutuzumab, independent epidemiology analysis reaffirms significant clinical and commercial potential in NRG1 fusion cancers – – MCLA-117 demonstrates limited clinical activity in Phase 1 trial – – Extensive panel of novel CD3 bispecific antibodies provides important insights and

MCLA-128, zenocutuzumab, Phase 1/2 eNRGy trial remains on track MCLA-117 program update to be presented at upcoming medical meeting Anand Mehra , M.D. to succeed Russell Greig , Ph.D. as Chairman and Paolo Pucci Nominated for Appointment to Merus Board of Directors UTRECHT, The Netherlands and

UTRECHT, The Netherlands and CAMBRIDGE, Mass. , March 12, 2020 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics TM ), today announced financial results